Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
October 24 2023 - 7:54AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of October 2023 (Report No. 6)
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
On October 24, 2023, SciSparc
Ltd. (the “Company”) issued a press release titled “SciSparc Granted Patent for its Core Technology From the Australian
Patent Office.” A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
This
Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration statements on Form
F-3 (File No. 333-269839, File No. 333-266047, File No. 333-233417, File No. 333-248670 and File No. 333-255408) and on Form S-8 (File
No. 333-225773) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
SciSparc Ltd. |
|
|
|
Date: October 24, 2023 |
By: |
/s/ Oz Adler |
|
Name: |
Oz Adler |
|
Title: |
Chief Executive Officer and Chief Financial Officer |
3
Exhibit
99.1
SciSparc
Granted Patent for its Core Technology From the Australian Patent Office
The
Company’s most recent patent further solidifies its position within the cannabis sector, complementing existing grants in the U.S., Europe,
and other key jurisdictions
TEL
AVIV, Israel, Oct. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty
clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous
system, announced today that it received a notice of acceptance for its patent application for the Combinations of Cannabinoids and N-Acylethanolamines
(the “Patent”). The Patent aligns seamlessly with the Company’s core technologies design to enhance cannabinoids’ safety
by using low dosages of active components while maintaining their therapeutic benefits.
The
Patent was granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation
for patents.
This
Patent adds to the collection of patents previously granted in Europe, the United States and Japan, supporting the innovation of SciSparc’s
technologies.
The
invention relates to compositions and methods for potentiating therapeutic effects and/or reducing the side-effects of selected cannabinoids
initially discovered in the cannabis plant. The Patent received protection on account of pharmaceutical compositions consisting of cannabinoids
and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treated conditions of such pharmaceutical
compositions.
About SciSparc Ltd.
(Nasdaq: SPRC):
SciSparc
Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s
focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the
Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment
of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale
of hemp seeds oil-based products on the Amazon.com Marketplace.
Forward-Looking
Statements:
This
press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses
the ability of its core technologies to enhance cannabinoids’ safety and therapeutic effects. Historical results of scientific
research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical
or even similar conclusions. Because such statements deal with future events and are based on SciSparc’s current expectations, they are
subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release
are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual
Report on Form 20-F filed with the SEC on May 1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission.
Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor
Contact:
IR@scisparc.com
Tel:
+972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2024 to May 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From May 2023 to May 2024